{
  "id": 16845457,
  "title": "Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026",
  "url": "https://urgent.news/2026/10/28/junshi-biosciences-announces-final-analysis-results-of-the-phase-3",
  "topic": "world",
  "section": "World",
  "published": "2026-10-28T03:49:20.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/junshi-biosciences-announces-final-analysis-results-of-the-phase-3-neotorch-study-at-esmo-congress-2026"
  },
  "original_language": "en",
  "account": null,
  "summary": "Perioperative toripalimab plus chemotherapy demonstrated significant and durable improvements in event-free survival and overall survival in patients with resectable stage II-III non-small cell lung cancer. SHANGHAI, Oct. 27, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}